Dr. Howard Fillit, the Co-Founder and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation (ADDF), authored an op-ed, "An Alzheimer’s Advance, Not a Cure-All: Donanemab promises progress. The FDA shouldn’t hold out for perfection," that appeared in the Wall Street Journal. Dr. Fillit underscores a critical paradigm shift in Alzheimer’s research and treatment: the need for a multimodal approach to combat this multifaceted disease.

Despite the high level of concern about Alzheimer’s disease, the poll revealed a significant knowledge gap regarding current treatments. Only a small percentage of voters feel they know "a lot" about available treatment options, with most having a superficial understanding. This lack of knowledge is particularly concerning given the widespread impact of the disease​​ and progress unfolding over the past few years.

Alzheimer’s disease is a primary concern for American voters, with nearly 94% considering it a serious health condition. In fact, Alzheimer’s is comparable to cancer in terms of perceived seriousness. The widespread concern among voters underscores the critical need for prioritizing Alzheimer’s in national health agendas and policy discussions​​.

Welcome to the first installment of our five-part series on the national perception of Alzheimer’s disease and progress in finding effective treatments. In this series, we will delve into the insights from a comprehensive national poll conducted by FTP Insights and Accelerate Advocacy in May 2024. This poll surveyed 1,028 registered voters to understand their views on Alzheimer’s, their knowledge about current treatments, and their support for new therapeutic approaches. Over the next few weeks, we’ll explore these themes in depth, providing valuable information and insights to help shape the future of Alzheimer’s research and advocacy. This blog overviews the critical findings from the 2024 national poll on Alzheimer’s disease.

The connection between heart health and brain function is more than just a preventative measure; it's a potential breakthrough in treating Alzheimer's disease.

In an era where Alzheimer's and dementia increasingly touch the lives of millions, advancements in diagnostic technologies offer a glimmer of hope.

In light of recent breakthroughs in Alzheimer's research, highlighted by the development of drugs such as donanemab, our community stands on the precipice of a new era. These developments, promising as they are, bring to the forefront the longstanding debate surrounding the amyloid hypothesis and the need to broaden our investigative horizons.

To tackle the Alzheimer’s epidemic effectively, we must broaden our lens to include vascular health as a vital component of prevention and treatment strategies.

Welcome to The Pulse, the cornerstone of the "Heart of the Solution" campaign, dedicated to shining a light on the indispensable link between vascular health and cognitive function.